Literature DB >> 21316416

Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

Caroline Bret1, Dirk Hose, Thierry Reme, Alboukadel Kassambara, Anja Seckinger, Tobias Meissner, Jean-François Schved, Tarik Kanouni, Hartmut Goldschmidt, Bernard Klein.   

Abstract

OBJECTIVE: The ADAM (a disintegrin and metalloproteinases) and the related ADAMTS (a disintegrin and metalloproteinases with thrombospondin) motifs metalloproteinases are membrane-anchored and secreted proteins exhibiting key roles in mediating cell adhesion, proteolytic shedding, and cell signaling. Dysregulation of these proteins has been observed in some pathologic states, including cancers. Their contribution to multiple myeloma, a plasma-cell neoplasia strongly dependent on bone marrow environment, has been poorly characterized.
MATERIALS AND METHODS: We analyzed the expression of genes encoding for these proteins and their inhibitors (tissue inhibitor of metalloproteinases [TIMP], reversion-inducing cysteine-rich protein with kazal motifs) in normal B-cell differentiation, primary malignant plasma cells, human myeloma cell lines, and various bone marrow environment cells. The prognostic value of the expression of these genes was analyzed in two independent series of newly diagnosed patients.
RESULTS: ADAM28 and ADAMTS6 were overexpressed in normal memory B cells, ADAM10 and ADAM19 in plasmablasts, and TIMP1 and TIMP2 in normal bone marrow plasma cells. ADAMTS9 was aberrantly expressed by primary malignant plasma cells and ADAM23 expression was associated with a bad prognosis, its expression being spiked in some primary myeloma cell samples. Bone marrow environment cells displayed distinct expression profiles for genes encoding for ADAMs and their inhibitors. They expressed ADAMTSs genes at a low level, with the exception of bone marrow stromal cells.
CONCLUSIONS: This study provides an overview of expression data related to ADAMs and ADAMTSs genes potentially involved in myeloma pathogenesis.
Copyright © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316416     DOI: 10.1016/j.exphem.2011.02.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Identification of commonly dysregulated genes in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation.

Authors:  W H Xiao; X L Qu; X M Li; Y L Sun; H X Zhao; S Wang; X Zhou
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

Review 2.  Biological aspects of angiogenesis in multiple myeloma.

Authors:  Eléonore Otjacques; Marilène Binsfeld; Agnes Noel; Yves Beguin; Didier Cataldo; Jo Caers
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

Review 3.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962

4.  TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Authors:  Chelsea Hope; Samuel J Ollar; Erika Heninger; Ellen Hebron; Jeffrey L Jensen; Jaehyup Kim; Ioanna Maroulakou; Shigeki Miyamoto; Catherine Leith; David T Yang; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Fotis Asimakopoulos
Journal:  Blood       Date:  2014-04-10       Impact factor: 22.113

5.  Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.

Authors:  Chelsea Hope; Simon Foulcer; Justin Jagodinsky; Sarah X Chen; Jeffrey L Jensen; Sanjay Patel; Catherine Leith; Ioanna Maroulakou; Natalie Callander; Shigeki Miyamoto; Peiman Hematti; Suneel S Apte; Fotis Asimakopoulos
Journal:  Blood       Date:  2016-06-03       Impact factor: 22.113

6.  Toxicogenomics profiling of bone marrow from rats treated with topotecan in combination with oxaliplatin: a mechanistic strategy to inform combination toxicity.

Authors:  Myrtle Davis; Jianying Li; Elaine Knight; Sandy R Eldridge; Kellye K Daniels; Pierre R Bushel
Journal:  Front Genet       Date:  2015-02-12       Impact factor: 4.599

7.  Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.

Authors:  Liesbeth Bieghs; Malene Brohus; Ida B Kristensen; Niels Abildgaard; Martin Bøgsted; Hans E Johnsen; Cheryl A Conover; Elke De Bruyne; Karin Vanderkerken; Michael T Overgaard; Mette Nyegaard
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

8.  The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice.

Authors:  Lakshini Herat; Caroline Rudnicka; Yasunori Okada; Satsuki Mochizuki; Markus Schlaich; Vance Matthews
Journal:  Int J Mol Sci       Date:  2017-04-21       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.